University of Massachusetts Medical Center, Worcester, MA, USA.
Penn State Cancer Institute, Hershey, PA, USA.
Med. 2024 Mar 8;5(3):176-178. doi: 10.1016/j.medj.2023.12.008.
As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.
随着晚期尿路上皮癌（UC）一线治疗的发展，后续治疗的最佳序贯仍不明确。III 期 THOR 研究比较了厄达替尼与化疗或免疫治疗在 FGFR3/2 改变的晚期 UC 中的疗效。THOR 研究提供了有价值的数据，为序贯治疗策略提供了信息，强化了 UC 中进行分子检测的必要性。
Zotero 插件